Literature DB >> 21094903

Structural basis for ligand recognition of incretin receptors.

Christina Rye Underwood1, Christoph Parthier, Steffen Reedtz-Runge.   

Abstract

The glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor are homologous G-protein-coupled receptors (GPCRs). Incretin receptor agonists stimulate the synthesis and secretion of insulin from pancreatic β-cells and are therefore promising agents for the treatment of type 2 diabetes. It is well established that the N-terminal extracellular domain (ECD) of incretin receptors is important for ligand binding and ligand specificity, whereas the transmembrane domain is involved in receptor activation. Structures of the ligand-bound ECD of incretin receptors have been solved recently by X-ray crystallography. The crystal structures reveal a similar fold of the ECD and a similar mechanism of ligand binding, where the ligand adopts an α-helical conformation. Residues in the C-terminal part of the ligand interact directly with the ECD and hydrophobic interactions appear to be the main driving force for ligand binding to the ECD of incretin receptors. Obviously, the-still missing-structures of full-length incretin receptors are required to construct a complete picture of receptor function at the molecular level. However, the progress made recently in structural analysis of the ECDs of incretin receptors and related GPCRs has shed new light on the process of ligand recognition and binding and provided a basis to disclose some of the mechanisms underlying receptor activation at high resolution.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21094903     DOI: 10.1016/B978-0-12-381517-0.00009-6

Source DB:  PubMed          Journal:  Vitam Horm        ISSN: 0083-6729            Impact factor:   3.421


  7 in total

1.  Identification of key residues involved in adrenomedullin binding to the AM1 receptor.

Authors:  H A Watkins; M Au; R Bobby; J K Archbold; N Abdul-Manan; J M Moore; M J Middleditch; G M Williams; M A Brimble; A J Dingley; D L Hay
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

2.  A novel DPP IV-resistant C-terminally extended glucagon analogue exhibits weight-lowering and diabetes-protective effects in high-fat-fed mice mediated through glucagon and GLP-1 receptor activation.

Authors:  Aisling M Lynch; Nupur Pathak; Varun Pathak; Finbarr P M O'Harte; Peter R Flatt; Nigel Irwin; Victor A Gault
Journal:  Diabetologia       Date:  2014-06-25       Impact factor: 10.122

3.  Monotreme glucagon-like peptide-1 in venom and gut: one gene - two very different functions.

Authors:  Enkhjargal Tsend-Ayush; Chuan He; Mark A Myers; Sof Andrikopoulos; Nicole Wong; Patrick M Sexton; Denise Wootten; Briony E Forbes; Frank Grutzner
Journal:  Sci Rep       Date:  2016-11-29       Impact factor: 4.379

4.  Generation of a highly diverse panel of antagonistic chicken monoclonal antibodies against the GIP receptor.

Authors:  Jennifer D Könitzer; Shreya Pramanick; Qi Pan; Robert Augustin; Sebastian Bandholtz; William Harriman; Shelley Izquierdo
Journal:  MAbs       Date:  2017-01-05       Impact factor: 5.857

Review 5.  Impact of non-proteinogenic amino acids in the discovery and development of peptide therapeutics.

Authors:  Yun Ding; Joey Paolo Ting; Jinsha Liu; Shams Al-Azzam; Priyanka Pandya; Sepideh Afshar
Journal:  Amino Acids       Date:  2020-09-18       Impact factor: 3.520

6.  A Non-Perturbative Molecular Grafting Strategy for Stable and Potent Therapeutic Peptide Ligands.

Authors:  Kathleen M Sicinski; Vittorio Montanari; Venkata S Raman; Jamie R Doyle; Benjamin N Harwood; Yi Chi Song; Micaella P Fagan; Maribel Rios; David R Haines; Alan S Kopin; Martin Beinborn; Krishna Kumar
Journal:  ACS Cent Sci       Date:  2021-02-15       Impact factor: 14.553

7.  Synthesis of the extracellular domain of GLP-1R by chemical and biotechnological approaches.

Authors:  János Szolomajer; Pál Stráner; Zoltán Kele; Gábor K Tóth; András Perczel
Journal:  RSC Adv       Date:  2022-08-26       Impact factor: 4.036

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.